News and Announcements
Altech Chemicals Ltd (ASX: ATC) FY15 Company Update
- Published January 29, 2015 2:40PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
After launching into a BFS for its high purity alumina (HPA) project, Altech selected Johor Bahru (Malaysia) as its preferred plant location due to significant cost savings – 40% opex and 50% capex savings. With its BFS progressing well, an optimised plant production rate of 4,000tpa; and wet processing for the aluminous clay beneficiation, was confirmed.
In November Altech appointed highly experienced accountant, Mr Shane Volk, as CFO/Company Secretary; Altech also received $0.46m R&D rebate.
Finally, Breakaway Research delivered a mid-point valuation of $0.25/ATC share; based on US$20/kg for HPA and Altech’s estimated opex US$8/kg, EV/EBITDA and DCF evaluation for only 7.5% of the full value of Altech’s HPA project ranged from US$260m-$360m.
Please click on the ‘Receive Information’ button below for more information or to register your interest.
ABOUT ALTECH CHEMICALS
Altech Chemicals Limited is aiming to become one of the world’s leading suppliers of a high-value product, 99.99% (4N) high purity alumina (HPA) (Al2O3).
HPA is the major source material for scratch-resistant artificial sapphire glass, which is used in the next generation of smartphones as well as a growing range of high performance electronic applications such as LED’s, semi-conductors, and phosphor TV screens. The global HPA market is approximately 19,040tpa and is expected to double over the coming decade.
Current HPA producers use an expensive and highly processed feedstock material such as aluminum metal to produce HPA. Altech has reported the ability to produce 4N HPA directly from an ore feedstock, such as aluminous clay. Altech employs a proven processing technology to extract HPA from its low-cost and low-impurity aluminous clay feedstock in Western Australia. The Company is now advancing a Bankable Feasibility Study (BFS) to develop a full-scale 3,000tpa production facility.
Altech is a chemical processing group focused on creating a high-margin product to meet the growing global demand for the next generation of high-performance technologies.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
